載入中
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
前收盤價
US$23.53
+US$0.71 · +3.11%
盤中時間採用ET。市場資料可能有所延遲。
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
日內區間
目前US$23.53
52週區間
目前US$23.53
盤中時間採用ET。市場資料可能有所延遲。
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
日內區間
目前US$23.53
52週區間
目前US$23.53
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7230.3萬 USD | 2852萬 USD | 716.3萬 USD | — | 625.4萬 USD |
| 銷貨成本 | 12.9萬 USD | 5593.3萬 USD | 4890萬 USD | 6908萬 USD | — |
| 毛利 | 7217.4萬 USD | −2741.3萬 USD | −4173.7萬 USD | −6908萬 USD | 625.4萬 USD |
| 研究與開發 | 6481.3萬 USD | 5593.3萬 USD | 4890萬 USD | 6998萬 USD | 6852.4萬 USD |
| 銷售、一般及管理費用 | 1960.8萬 USD | 1800.7萬 USD | 2290.9萬 USD | 2393.4萬 USD | 2878萬 USD |
| 營業費用 | 8442.1萬 USD | 1800.7萬 USD | 2290.9萬 USD | 2503.4萬 USD | 1.39億 USD |
| 利息收入 | 599.6萬 USD | 557.3萬 USD | 345.1萬 USD | 102.2萬 USD | 30.2萬 USD |
| 折舊和攤銷 | 12.9萬 USD | 12.9萬 USD | 45萬 USD | 49.8萬 USD | 46.6萬 USD |
| 營業利益 | −1211.8萬 USD | −4542萬 USD | −6464.6萬 USD | −9411.4萬 USD | −1.33億 USD |
| 淨利 | −612.2萬 USD | −4017.7萬 USD | −6122.8萬 USD | −9309.2萬 USD | −1.3億 USD |
公司資料更新於 2026年10月12日。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1389.87萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM790.49萬0.01%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI697.86萬0.07%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF443.53萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO190.15萬0.01%180億 USD0.06%US$112.66+0.50%
Vanguard Health Care ETFVHT112.38萬0.01%220億 USD0.09%US$319.01+1.64%
iShares Micro-Cap ETFIWC96.73萬0.07%13.17億 USD0.60%US$183+0.11%
Fidelity Enhanced Small Cap ETFFESM52.02萬0.01%64.1億 USD0.28%US$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
